A Question of Policy: When is a PBPK Model “Good Enough” for Chemical Risk Assessment?
Dr. Frédéric Y. Bois |
Senior Scientific Advisor and Head of Mechanistic Modelling at CERTARA UK, Simcyp
Pharmacology offers different risk contexts from environmental risk assessment, and the benefit/risk balance is under close scrutiny from all stakeholders. In vitro and in vivo data availability is also more prevalent in pharmacology, which leads to specific decision rules for model validation.